Moreover, HER-2 and EGFR-targeted CAR-T cell therapies demonstrated toxicity not only for tumor cells but also for normal cells that shared the antigen (on-Target, off-Tumor Toxicity). The gene discussed is ERBB2; the disease is neoplasm.